A Phase I Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
Latest Information Update: 22 May 2023
Price :
$35 *
At a glance
- Drugs Tivozanib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Kyowa Kirin
- 16 May 2023 Status changed from recruiting to discontinued.
- 04 Nov 2021 Planned number of patients changed from 96 to 128.
- 04 Nov 2021 Planned End Date changed from 1 Feb 2022 to 1 Dec 2022.